The page you requested could not be found. For your convenience, we started a search for you with the terms "news new published evidence reinforces imp".
As current MDIs contain hydrofluorocarbon propellants, it would be beneficial to find ways to reduce carbon emissions without compromising patient safety.
This lab study investigated a way to optimize the modelled lung dose per actuation while at the same time minimizing the carbon emissions from the MDI
Depending on the pMDI/spacer system chosen the delivery of medication can vary significantly and as a result will have implications on the potential carbon footprint.
In this case, the use of the AeroChamber Plus* Flow-Vu* VHC could potentially reduce the carbon footprint by three fold compared to the alternative spacers.
By maximizing the amount of each puff reaching the lungs the patient is likely to be able to get relief sooner and reduce the amount of puffs needed.
Depending on the pMDI/spacer system chosen the delivery of medication can vary significantly and as a result will have implications on the potential carbon footprint.
In this case, the use of the AeroChamber Plus* Flow-Vu* VHC could potentially reduce the carbon footprint by three fold compared to the alternative spacers.
By maximizing the amount of each puff reaching the lungs the patient is likely to be able to get relief sooner and reduce the amount of puffs needed.
A new study uses Functional Respiratory Imaging (FRI) to assess and compare the performance of a Metered Dose Inhaler (MDI) alone, an MDI with multiple brands of spacers, and a Dry Powdered Inhaler (DPI) alone. Using Functional Respiratory Imaging (FRI), the study explores the combined impact of inhaler mechanics, patient physiology and patient technique. Results suggest using an AeroChamber Plus* Flow-Vu* Spacer combined with an MDI results in superior medication delivery to the lungs, compared to the other spacer brands tested with MDIs, MDIs alone, and DPIs alone.
